"10.1371_journal.pone.0078048","plos one","2013-10-29T00:00:00Z","Barry S Peters; Melissa Perry; Anthony S Wierzbicki; Lisa E Wolber; Glen M Blake; Nishma Patel; Richard Hoile; Alastair Duncan; Ranjababu Kulasegaram; Frances M K Williams","Department of Infectious Diseases, Kings College London, London, United Kingdom; Honorary Consultant Physician, Guys and St Thomas’ Foundation Hospitals, London, United Kingdom; Department of HIV and GU Medicine Physician, Guys and St Thomas’ Foundation Hospitals, London, United Kingdom; Department of Chemical Pathology, Guys and St Thomas’ Foundation Hospitals, London, United Kingdom; Twins Research Unit, Department of Rheumatology, Kings College London, London, United Kingdom; Department of Nuclear Medicine, Kings College London, London, United Kingdom; School of Medicine, Kings College London, London, United Kingdom; Department of Dietetics, Guys and St Thomas’ Foundation Hospitals, London, United Kingdom; Department of HIV and GU Medicine, Guys and St Thomas’ NHS Trust, London, United Kingdom","Conceived and designed the experiments: BP AW FW RK. Performed the experiments: BP MP NP RK RH AD. Analyzed the data: BP AW GB LW FW. Contributed reagents/materials/analysis tools: LW GB. Wrote the manuscript: BP FW LW AW FW GB NP AD.","The authors have the following interests. Within the past 36 months, the following financial relationships are disclosed for the authors: BSP: received a total for less than $1500 USD, for an advisory board in past 36 months from Abbott Laboratories, GlaxoSmithKline, Merck, & ViiV pharmaceuticals. Grants from GlaxoSmithKline awarded to Dr Peters as above for this study, and as above, a grant from ViiV for a follow-up study on this cohort. Conference attendance funded by Abbott Laboratories for attendance IAS (International AIDS Conference) 2012. RK: received grants, travel sponsorship, research support, or consultancy fees, or has served on advisory boards for ViiV, Merck Sharp & Dohme, Abbott, Bristol-Myers Squibb, Janssen, and Gilead Sciences. The other authors have stated that there have been no financial or other relevant relationships or conflicts of interest within the previous 36 months. This project was in part supported by an unrestricted educational grant from GlaxoSmithKline pharmaceuticals. A subsequent unrestricted grant to look at prospective follow-up of patients described in this manuscript has been granted by ViiV pharmaceuticals and is in progress. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","10","Barry S Peters","BSP",10,TRUE,4,6,5,7,TRUE,TRUE,FALSE,0,NA,FALSE
